Key result
An isolated elevation of cardiac troponin after percutaneous coronary intervention is not associated with an adverse prognosis and should not be considered an independent predictor of late adverse outcomes.
Caution is advised when interpreting clinical trials using type 4a MI (periprocedural MI defined by isolated troponin elevation) as a primary endpoint, as isolated post-PCI troponin elevation is not clearly linked to adverse prognosis.
Caution advised when trials use isolated troponin elevation to define type 4a MI; leaves open its validity as a prognostic endpoint.
The recently updated Universal Defi nition of Myocardial infarction (MI) arbitrarily defi ned periprocedural MI (type 4a) by elevation of cardiac troponin (cTn) values > 5 the upper reference limit (URL) in patients with normal baseline values or a rise of cTn values > 20% if the baseline values are elevated, together with either angina or new ECG changes or angiographic loss of patency of a coronary artery or a side branch or persistent slow or no-fl ow or embolization, or imaging demonstration of new loss of viable myocardium. Although an association between CK-MB elevations and adverse prognosis after PCI has been documented, existing data do not however support the statement that an isolated elevation of cTn after PCI is associated with an adverse prognosis after PCI; increased cTn levels before PCI seem far more predictive of future events than a periprocedural increase itself. Caution should be paid in the interpretation of clinical trials using type 4a MI as a primary endpoint. Nevertheless, patients with periprocedural myocardial damage should be treated as a higher-risk cohort, carefully monitored and receive an intensifi ed secondary prevention program.
No takes yet. Share an insight, caveat, or question.
Zimarino et al. (2012) conducted an editorial in Periprocedural myocardial infarction (type 4a) after percutaneous coronary interventions. Cardiac troponin (cTn) measurement was evaluated. An isolated elevation of cardiac troponin after percutaneous coronary intervention is not associated with an adverse prognosis and should not be considered an independent predictor of late adverse outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: